Curidium Discovers Significantly Different Patient Subgroups in Schizophrenia and Bipolar Disorder 
Curidium Medica plc, today announced that it has discovered four unique and statistically significantly different subgroups of schizophrenia/bipolar disorder patients based on their gene expression profiles.